AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up
20th February 2026 Uncategorised 0AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its Calquence plus Venclexta as the first all-oral, fixed-duration regimen for first-line chronic lymphocytic leukemia.
More: AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up
Source: fierce